We only have this paper's title and publication details.
Read it at the sourceRetrospective study evaluates favipiravir's effects on laboratory parameters in COVID-19 patients with chronic kidney disease, suggesting important considerations for treatment safety.
No takes yet. Share an insight, caveat, or question.
Acet et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: